Sign up to save your podcasts
Or
Share Tanya Siddiqi, MD - Addressing Patient Needs With CAR T-Cell Therapy in the Treatment of CLL/SLL: Preparing for an Evolving Treatment Paradigm
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Tanya Siddiqi, MD - Addressing Patient Needs With CAR T-Cell Therapy in the Treatment of CLL/SLL: Preparing for an Evolving Treatment Paradigm
Please visit answersincme.com/DTC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancers discusses management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and the future use of CAR T-cell therapies. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs in the management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); Describe the clinical evidence of novel and emerging therapies being investigated to address unmet therapeutic needs in the management of CLL/SLL; and Outline considerations for optimizing the future use of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with relapsed/refractory CLL/SLL.
View all episodes
By Answers in CME
5
55 ratings
Please visit answersincme.com/DTC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancers discusses management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and the future use of CAR T-cell therapies. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs in the management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); Describe the clinical evidence of novel and emerging therapies being investigated to address unmet therapeutic needs in the management of CLL/SLL; and Outline considerations for optimizing the future use of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with relapsed/refractory CLL/SLL.
More shows like CME in Minutes: Education in Oncology & Hematology
View all
JAMA Editors' Summary
129 Listeners
NEJM This Week
324 Listeners
Journal of Clinical Oncology (JCO) Podcast
38 Listeners
This Week in Cardiology
862 Listeners
JAMA Clinical Reviews
493 Listeners
The Curbsiders Internal Medicine Podcast
3,332 Listeners
JAMA Medical News
87 Listeners
CME in Minutes: Education in Cardiology & Pulmonology
3 Listeners
CME in Minutes: Education in Dermatology
3 Listeners
CME in Minutes: Education in Primary Care
5 Listeners
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
4 Listeners
CME in Minutes: Education in Ophthalmology
0 Listeners